FDA Approves VEPPANU — Arvinas Operations, Inc.

# FDA Approves Arvinas' VEPPANU (Vepdegestrant) for Oral Administration Arvinas Operations, Inc. received FDA approval for VEPPANU (vepdegestrant), an oral selective estrogen receptor degrader (SERD), positioning the company to compete in the growing market for advanced hormone receptor-positive breast cancer treatments and potentially expanding treatment accessibility through oral formulation compared to existing intravenous alternatives. The approval could strengthen Arvinas' oncology portfolio and capture significant market share among patients seeking convenient at-home dosing options in a therapeutic category projected to see